YBX1 and acute myeloid leukemia: In order to generate a global view on the functional properties of YBX1 in AML, we performed a genome-wide CRISPR-Cas9 screen in MOLM13 cells comparing the genetic vulnerabilities of YBX1-knockout and control cells (Fig. 5A).